Antidepressants interact with the skin in more ways than most people realize, ranging from nuisance side effects like excessive sweating and easy bruising to rare but serious reactions that need immediate medical attention. Some of these drugs can also change how your skin responds to sunlight or alter its pigmentation over time. What makes this especially interesting is that the skin is not just a passive bystander: it has its own serotonin-producing machinery, which means medications designed to alter serotonin signaling in the brain inevitably tinker with skin biology too.
Why Your Skin Cares About Serotonin
Most people associate serotonin with mood, but your skin cells actively produce it. Researchers have detected the enzyme responsible for making serotonin in epidermal melanocytes (the cells that produce pigment), dermal fibroblasts (cells in the deeper layer of skin), and to a lesser extent in keratinocytes, the cells that form the skin’s outermost barrier.1PubMed Central. Characterization of Serotonin and N-acetylserotonin Systems in the Human Epidermis and Skin Cells Serotonin and its metabolites are measurable in human skin tissue, not just in the bloodstream. This local serotonin system appears to play a role in pigmentation, inflammation, and wound repair. So when you take a selective serotonin reuptake inhibitor (SSRI) or another antidepressant that changes serotonin levels, the effects ripple through the skin in ways that go well beyond what the prescribing information typically highlights.
Platelets add another layer to this. They rely on the same serotonin transporter that SSRIs block. Normally, platelets vacuum up serotonin from the blood and store it in dense granules, releasing it when they need to help form a clot. SSRIs interfere with that storage process, which has direct consequences for how easily you bruise and bleed.2PubMed Central. Selective Serotonin Reuptake Inhibitors and Associated Bleeding Risks: A Narrative and Clinical Review
Sweating and Flushing
Excessive sweating is one of the most common skin-related complaints people have on antidepressants, and it is not limited to one drug class. Both SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine can trigger it. Sweat glands are controlled by the sympathetic nervous system through a chain of signals that ultimately uses a different neurotransmitter, acetylcholine, at the final step before the gland itself fires. The interplay between serotonin and norepinephrine signaling upstream can disrupt normal sweat regulation, leading to drenching night sweats or daytime hyperhidrosis that some people find genuinely debilitating.3Medical Hypotheses. To sweat or not to sweat? A hypothesis on the effects of venlafaxine and SSRIs
This tends to be dose-related: the higher the dose, the more likely you are to notice it. Flushing, the sudden reddening of the face and upper body, can accompany the sweating or appear on its own, and it is more common with SNRIs than with SSRIs alone. If this side effect is intolerable, your prescriber may try lowering the dose or switching to an antidepressant with a different mechanism. Anticholinergic medications have been used off-label to manage drug-induced sweating, though they come with their own side effects.
Easy Bruising and Unusual Bleeding
Because SSRIs reduce serotonin storage in platelets, they impair the clotting cascade in a clinically meaningful way. People on SSRIs sometimes notice that they bruise more easily, develop small red or purple dots on the skin (petechiae), or find larger discolored patches (ecchymoses) after minor bumps. These aren’t just cosmetic. The bleeding risk becomes especially relevant if you’re also taking nonsteroidal anti-inflammatory drugs like ibuprofen or low-dose aspirin, both of which independently affect platelet function.4Journal of the American Academy of Dermatology. Cutaneous effects of the most commonly used antidepressant medication, the selective serotonin reuptake inhibitors
This doesn’t mean everyone on an SSRI will bruise like a peach. Many people never notice a difference. But if you’re already on blood-thinning medications, or you’re scheduled for surgery, it’s worth flagging your antidepressant to the treating physician so they can assess cumulative bleeding risk.
Photosensitivity and Skin Color Changes
Certain antidepressants can make your skin more sensitive to ultraviolet light. This has been documented across drug classes, though the bulk of early research focused on older tricyclic antidepressants (TCAs) and antipsychotics. A photosensitivity reaction typically shows up as an exaggerated sunburn, a rash, or skin discoloration in sun-exposed areas after what would normally be harmless UV exposure.5PubMed. Photosensitivity associated with antipsychotics, antidepressants and anxiolytics A systematic review of TCA-induced photosensitivity found that the most common presentation was photo-distributed hyperpigmentation, meaning the skin darkens in the areas that get the most sunlight.6PubMed. Tricyclic antidepressant-induced photosensitivity; A case report and systematic review
Pigmentation changes can also happen independently of sunlight. A review of psychotropic drug-associated hyperpigmentation identified multiple antidepressants as culprits, including amitriptyline, imipramine, citalopram, sertraline, and mirtazapine, among others. A particularly sneaky aspect of this side effect is that it can appear many years after starting the medication, making it easy to miss the connection. Skin biopsies in these cases typically show melanin deposits in the deeper layers of the skin.7PubMed. Amitriptyline-induced cutaneous hyperpigmentation: case report and review of psychotropic drug-associated mucocutaneous hyperpigmentation
There’s laboratory evidence that at least one SSRI, fluoxetine, directly ramps up melanin production. In cell and mouse studies, fluoxetine increased the activity of tyrosinase, the key enzyme in pigment synthesis, and boosted levels of several proteins that drive melanin production. This led to visibly darker hair pigmentation in mice. The pathway appears to involve the serotonin 1A receptor.8PubMed. Up-regulation of melanin synthesis by the antidepressant fluoxetine Whether this translates to noticeable skin darkening in humans at standard doses is still unclear, but it offers a plausible mechanism for the pigmentation changes clinicians have observed.
If you are on an antidepressant and notice unusual skin darkening, especially in sun-exposed areas, bring it up with your dermatologist and prescriber. Diligent sunscreen use is a reasonable precaution for anyone on a medication known to cause photosensitivity.
Rashes, Hives, and Drug Eruptions
Allergic-type skin reactions are a recognized side effect across most antidepressant classes, though they are not especially common. The most frequent presentations are generalized rashes (exanthems) and hives (urticaria), sometimes with swelling beneath the skin. Among the antidepressants, bupropion has the highest reported rate of rash and itching at roughly 3.7%, while SSRIs like fluoxetine, paroxetine, sertraline, and venlafaxine each come in below 1%.9Journal of Psychiatry Spectrum. Escitalopram-associated Cutaneous Reactions: Insights from a Case Series Escitalopram is rarely reported to cause these kinds of reactions.
Most drug rashes resolve after the medication is stopped, though it can take days to a couple of weeks. In some cases, a different antidepressant from the same class can be tried without the rash returning, since the allergic trigger is often specific to the drug’s molecular structure rather than to the entire class.
Rare but Serious Skin Reactions
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are the most feared drug-related skin reactions. They involve widespread blistering and detachment of the skin’s surface and can be life-threatening. These conditions are strongly associated with certain anticonvulsants and antibiotics, but a few antidepressants have also been implicated. A large European case-control study found a statistically significant association between sertraline and SJS/TEN, with a relative risk around 11 compared to non-users.10Journal of Investigative Dermatology. Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Assessment of Medication Risks with Emphasis on Recently Marketed Drugs. The EuroSCAR-Study
A separate population-based study looked specifically at commonly prescribed outpatient medications and found that fluoxetine and mirtazapine were associated with increased risk as well, though with lower odds ratios. The absolute risk was small: roughly 0.2 to 1.6 per 100,000 new users for fluoxetine and mirtazapine. That same study found no association for citalopram, sertraline, paroxetine, or venlafaxine despite studying over 100,000 new users of each.11PubMed. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study The conflicting findings for sertraline between the two studies illustrate why this evidence base remains unsettled: different study designs, populations, and control methods produce different estimates.
The practical takeaway is that SJS/TEN from antidepressants is extremely rare but not impossible. Any new rash that involves blistering, mucosal erosions (painful sores in the mouth, eyes, or genitals), or rapidly spreading skin tenderness within the first few weeks of starting or switching a medication warrants immediate medical evaluation.
Hair Loss
Thinning hair is an underappreciated side effect of several antidepressants, and it can be distressing enough to make people consider stopping treatment. A large retrospective cohort study compared hair loss risk across different antidepressants and found that bupropion carried the highest risk. When measured against fluoxetine, bupropion users were about 46% more likely to experience hair loss over two years. Paroxetine and fluoxetine had the lowest risk among the drugs studied.12PubMed. Risk of hair loss with different antidepressants: a comparative retrospective cohort study The researchers estimated that for every 242 people treated with bupropion instead of fluoxetine over two years, one additional person would experience hair loss.
Hair loss from antidepressants is usually a diffuse thinning rather than patchy bald spots, and it typically develops gradually, making it easy to attribute to aging or stress. If you notice significant shedding after starting a new antidepressant, mention it to your doctor — switching medications sometimes resolves the issue.
Dry Skin and Mucous Membranes
Tricyclic antidepressants are the biggest offenders here because of their anticholinergic activity. Acetylcholine drives secretions throughout the body, and when you block it, the result is dry mouth, dry eyes, and sometimes noticeably drier skin. Dry mouth is one of the most commonly reported side effects of TCAs.13PubMed Central. Psychotropic Drugs in Dermatology Part 1: Anti-depressants and Mood Stabilisers The dryness can affect skin barrier function, potentially making conditions like eczema worse or leaving skin feeling tight and flaky. Staying hydrated, using a humidifier, and applying emollients regularly can help manage this.
SSRIs and SNRIs have much less anticholinergic activity, so dryness is less of an issue with those classes. However, some people on SSRIs still report dry mouth, and the sweating discussed earlier can paradoxically coexist with dryness elsewhere — you may be drenching your sheets at night while your lips crack from dehydration.
When Antidepressants Help Skin Conditions
The relationship between antidepressants and skin is not purely one of side effects. A systematic review examining antidepressant use in five common inflammatory skin disorders — chronic urticaria, psoriasis, atopic dermatitis, other eczema, and alopecia areata — found that treatment with antidepressants consistently reduced skin symptoms. The authors argued that the benefit may go beyond simply treating the depression or anxiety that often accompanies chronic skin conditions, pointing instead to direct anti-inflammatory properties of the drugs themselves.14PubMed. Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review
This makes biological sense. SSRIs have been shown in lab and animal studies to modulate immune pathways, dampen pro-inflammatory signaling, and even have antimicrobial effects. Research into topical SSRI formulations for psoriasis has found that several SSRIs reduce pro-inflammatory cytokine production in immune cells in culture, and one — fluvoxamine — showed the most promising anti-inflammatory results in a mouse model of psoriasis-like skin inflammation.15European Journal of Pharmaceutical Sciences. Combining in vitro, in vivo, and in silico approaches to evaluate the effect of serotonergic-based topical therapies on mild to moderate psoriasis These are still early-stage findings, and no topical SSRI is approved for any skin condition, but the research suggests a future where these drugs might be repurposed as skin treatments.
SSRIs have also shown antimicrobial activity both in the lab and in animal studies, including effects on bacterial biofilms. This has generated interest in their potential role in treating slow-healing wounds and skin diseases where microbial imbalance plays a role.16PubMed Central. The potential action of SSRIs in the treatment of skin diseases including atopic dermatitis and slow-healing wounds Emerging evidence also points to SSRIs improving wound healing through effects on blood vessel formation and immune regulation, though this work has not yet been tested comprehensively in human skin wounds.17Frontiers in Pharmacology. Serotonin-modulating therapies for the management of chronic wounds
Bupropion and Psoriasis Flares
While some antidepressants may calm inflammatory skin conditions, bupropion stands out as a notable exception when it comes to psoriasis. Multiple case reports describe patients with pre-existing psoriasis who experienced severe flares — including erythrodermic psoriasis, where nearly the entire body surface turns red and inflamed — within weeks of starting bupropion.18PubMed Central. Erythrodermic Psoriasis Exacerbated by Bupropion In one series, three patients with known psoriasis developed severe pustular or erythrodermic exacerbations within three to five weeks of starting the drug.19British Journal of Dermatology. Generalized pustular and erythrodermic psoriasis associated with bupropion treatment
Bupropion works differently from SSRIs — it primarily affects dopamine and norepinephrine rather than serotonin — so its mechanism for triggering psoriasis flares is likely distinct. This remains an under-recognized side effect, and clinicians who treat patients with both depression and psoriasis should weigh this risk when choosing an antidepressant. A case-control study found a borderline association between antidepressant use generally and new-onset psoriasis, though the sample size was too small to reach statistical significance.20PubMed Central. Antidepressants and the Risk of Psoriasis Induction: A Case–Control Study
Why Side Effects Vary So Much Between People
One puzzle is why your coworker takes the same SSRI at the same dose and has zero skin issues while you break out in a rash or soak through your shirts. Part of the answer lies in individual differences in drug metabolism. Your liver processes most antidepressants through a family of enzymes, and genetic variation in these enzymes can produce large differences in how much active drug ends up in your bloodstream. A review of the literature concluded that individual genetic characteristics, along with factors like age, sex, and diet, play a crucial role in whether adverse effects develop.21PubMed. The Influence of Genetic Variations and Drug Interactions Based on Metabolism of Antidepressants and Anticonvulsants
That said, the genetics-to-side-effects link is not as straightforward as it might seem. In a study of patients taking either nortriptyline or escitalopram, genetic variation in drug-metabolizing enzymes did not predict total side-effect burden or whether patients would drop out of the study. Blood levels of the antidepressant were only related to a handful of specific side effects, including dry mouth and dizziness.22PubMed Central. Exploring the role of drug-metabolising enzymes in antidepressant side effects So while metabolism matters, it is not the whole story. Other variables — concurrent medications, underlying skin conditions, immune system quirks, even stress levels — likely contribute to who develops skin-related side effects and who doesn’t.
Discontinuation and Skin Sensations
Stopping an antidepressant, especially abruptly, can produce its own set of skin-related symptoms. The most widely discussed is the so-called “brain zap” — a brief electric shock-like sensation that can radiate through the head, face, or body. While these are more neurological than dermatological, some people describe tingling, prickling, or crawling sensations across the skin during antidepressant withdrawal. Venlafaxine is particularly associated with severe shock-like sensations during dose reduction, with symptoms persisting for days after complete discontinuation in reported cases.23PubMed. Shock-like sensations during venlafaxine withdrawal
These withdrawal-related sensations are distinct from the drug side effects discussed elsewhere in this article — they emerge when the medication leaves your system rather than while it is present. Gradual tapering under medical supervision is the standard approach to minimizing them. If you are experiencing unusual skin sensations while reducing your dose, let your prescriber know so they can adjust the tapering schedule.